LV12859B - Farmaceitiskas kompozīcijas ar morfīnu intranazālai ievadīšanai un to iegūšanas paņēmieni - Google Patents
Farmaceitiskas kompozīcijas ar morfīnu intranazālai ievadīšanai un to iegūšanas paņēmieni Download PDFInfo
- Publication number
- LV12859B LV12859B LVP-01-169A LV010169A LV12859B LV 12859 B LV12859 B LV 12859B LV 010169 A LV010169 A LV 010169A LV 12859 B LV12859 B LV 12859B
- Authority
- LV
- Latvia
- Prior art keywords
- morphine
- acceptable salt
- pharmaceutically acceptable
- absorption
- pharmaceutical composition
- Prior art date
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title claims abstract description 306
- 229960005181 morphine Drugs 0.000 title claims abstract description 150
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 145
- 238000010521 absorption reaction Methods 0.000 claims abstract description 112
- 150000003839 salts Chemical class 0.000 claims abstract description 75
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 17
- 230000004044 response Effects 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 239000003623 enhancer Substances 0.000 claims description 65
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 23
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 23
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 23
- 239000005642 Oleic acid Substances 0.000 claims description 23
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 23
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 23
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 23
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 18
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 16
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 229960004025 sodium salicylate Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 10
- -1 polyoxyethylene Polymers 0.000 claims description 10
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229940099429 polyoxyl 40 stearate Drugs 0.000 claims description 8
- 206010002091 Anaesthesia Diseases 0.000 claims description 7
- 230000037005 anaesthesia Effects 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- 229920000136 polysorbate Polymers 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 229960002969 oleic acid Drugs 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 239000003833 bile salt Substances 0.000 claims description 5
- 229940093761 bile salts Drugs 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims 6
- 239000004909 Moisturizer Substances 0.000 claims 5
- 230000001333 moisturizer Effects 0.000 claims 5
- 239000007853 buffer solution Substances 0.000 claims 4
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229920000084 Gum arabic Polymers 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 241000978776 Senegalia senegal Species 0.000 claims 2
- 239000000205 acacia gum Substances 0.000 claims 2
- 235000010489 acacia gum Nutrition 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229950004053 octoxinol Drugs 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 abstract description 141
- 230000000202 analgesic effect Effects 0.000 abstract description 13
- 229960004715 morphine sulfate Drugs 0.000 description 91
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 91
- 229920001213 Polysorbate 20 Polymers 0.000 description 66
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 66
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 66
- 239000003814 drug Substances 0.000 description 31
- 230000036470 plasma concentration Effects 0.000 description 31
- 229940079593 drug Drugs 0.000 description 29
- 229940124274 edetate disodium Drugs 0.000 description 12
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 229940001584 sodium metabisulfite Drugs 0.000 description 10
- 235000010262 sodium metabisulphite Nutrition 0.000 description 10
- 230000008719 thickening Effects 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 8
- 230000036592 analgesia Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 229960004418 trolamine Drugs 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000007979 citrate buffer Substances 0.000 description 7
- 239000003906 humectant Substances 0.000 description 7
- 239000007922 nasal spray Substances 0.000 description 7
- 229940068977 polysorbate 20 Drugs 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229940097496 nasal spray Drugs 0.000 description 6
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 6
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 4
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 4
- 101150049479 CCNC gene Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 241000220479 Acacia Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- 206010038678 Respiratory depression Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940066429 octoxynol Drugs 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- SVTKSKRNLMAUKF-HAIKCVHQSA-N (4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O SVTKSKRNLMAUKF-HAIKCVHQSA-N 0.000 description 2
- RSMAIGNNANZTLL-VYKNHSEDSA-N (4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O RSMAIGNNANZTLL-VYKNHSEDSA-N 0.000 description 2
- OIALAIQRYISUEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]e Polymers CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OIALAIQRYISUEV-UHFFFAOYSA-N 0.000 description 2
- 244000202285 Acrocomia mexicana Species 0.000 description 2
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
- WAEXKFONHRHFBZ-ZXDZBKESSA-N Morphine-3-glucuronide Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WAEXKFONHRHFBZ-ZXDZBKESSA-N 0.000 description 2
- GNJCUHZOSOYIEC-GAROZEBRSA-N Morphine-6-glucuronide Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)O)O[C@@H]1[C@]52CCN3C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O GNJCUHZOSOYIEC-GAROZEBRSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001113 butorphanol Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 2
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 229960003066 morphine tartrate Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- FSUXDJDFTDDUJZ-KBQPJGBKSA-N [(4r,4ar,7s,7ar,12bs)-9-hydroxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-yl] sulfate Chemical compound O([C@H]1[C@H](C=C[C@H]23)OS(O)(=O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O FSUXDJDFTDDUJZ-KBQPJGBKSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940052404 nasal powder Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (29)
- LV 12859 IZGUDROJUMA FORMULA 1. Farmaceitiska kompozīcija intranazāla ievadīšanai, kurā ietilpst morfīns vai tā farmaceitiski pieņemams sāls ar pH no 3,0 līdz 7,0.
- 2. Farmaceitiska kompozīcija saskaņā ar l.punktu, kurā ietilpst morfina vai tā farmaceitiski pieņemama sāls terapeitiski efektīvs daudzums, lai izsauktu zīdītāju sāpju remdināšanas vai anestēzijas reakciju.
- 3. Farmaceitiska kompozīcija saskaņā ar l.punktu, kurā papildus ietilpst morfins vai tā farmaceitiski pieņemams sāls kopā ar nazāla ievadīšanas (padeves) sistēmu.
- 4. Farmaceitiska kompozīcija saskaņā ar 3.punktu, kas atšķiras ar to, ka morfins vai tā farmaceitiski pieņemams sāls disperģēts ūdens vai neūdens kompozīcijā.
- 5. Farmaceitiska kompozīcija saskaņā ar 4.punktu, kas a t š ķ i r a s ar to, ka morfina vai tā farmaceitiski pieņemama sāls koncentrācija ir zemāka par 50 % mas./mas.
- 6. Farmaceitiska kompozīcija saskaņā ar 4.punktu, kas a t š ķ i r a s ar to, ka morfina vai tā farmaceitiski pieņemama sāls koncentrācija ir zemāka par 10 % mas./mas.
- 7. Farmaceitiska kompozīcija saskaņā ar 4.punktu, kas a t š ķ i r a s ar to, ka morfins vai tā farmaceitiski pieņemams sāls disperģēts suspensijā, šķīdumos, pulveros, gelos, ziedēs un krēmos.
- 8. Farmaceitiska kompozīcija saskaņā ar 3.punktu, kas a t š ķ i r a s ar to, ka nazāla ievadīšanas (padeves) sistēmā ietilpst buferšķīdums morfina vai tā farmaceitiski pieņemama sāls pH uzturēšanai, biezinātājs, mitrinātājs, absorbcijas palielinātājs un šo komponentu kombinācijas.
- 9. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kurā papildus ietilpst viena vai vairākas farmaceitiskas palīgvielas. 2
- 10. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kurā papildus ietilpst dispersijas (suspensijas) stabilizators.
- 11. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kas a t š ķ i r a s ar to, ka buferšķīdumu izvēlas no grupas, kas sastāv no acetāta, citrāta, prolamīna, karbonāta, fosfāta un šo buferšķīdumu kombinācijām.
- 12. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kas a t š ķ i r a s ar to, ka biezinātāju izvēlas no grupas, kas sastāv no metilcelulozes, ksantāna sveķiem, karboksimetilcelulozes, hidroksipropilcelulozes, karbomēra, polivinilspirta, alginātiem, gumiarābika, hitozāna un šo biezinātāju kombinācijām.
- 13. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kas a t š ķ i r a s ar to, ka mitrinātāju izvēlas no grupas, kas sastāv no sorbīta, glicerīna, minerāleļļas, augu eļļas un šo mitrinātāju kombinācijām.
- 14. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kas a t š ķ i r a s ar to, ka absorbcijas palielinātāju izvēlas no grupas, kas sastāv no nātrija laurilsulfata, nātrija salicilāta, oleīnskābes, lecitīna, dehidratēta spirta, Tween, Span, polioksila 40 stearāta, polioksietilēna 50 stearāta, dinātrija edetāta, propilēnglikola, glicerolmonooleāta, fuziātiem, žulta sāļiem, oktoksinola un šo absorbcijas palielinātāju kombinācijām.
- 15. Farmaceitiska kompozīcija saskaņā ar 8.punktu, kas a t š ķ i r a s ar to, ka absorbcijas palielinātāju izvēlas no grupas, kas sastāv no anjonu, katjonu un nekatjonu absorbcijas palielinātājiem un to kombinācijām.
- 16. Paņēmiens zīdītāju sāpju remdināšanas vai anestēzijas reakcijas izsaukšanai, kurā ietilpst morfīna un tā farmaceitiski pieņemama sāls ar pH no 3,0 līdz 7,0 terapeitiski efektīva daudzuma ievadīšana nazāli.
- 17. Paņēmiens zīdītāju sāpju remdināšanas vai anestēzijas reakcijas izsaukšanai, kurā ietilpst morfīna un tā farmaceitiski pieņemama sāls ar pH no 3,0 līdz 7,0 terapeitiski efektīva daudzuma ievadīšana zīdītājiem kopā ar nazāla ievadīšanas (padeves) sistēmu. 3 LV 12859
- 18. Paņēmiens saskaņā ar 17.punktu, kas atšķiras ar to, ka morfīns vai ta farmaceitiski pieņemams sāls disperģēts ūdens vai neūdens kompozīcijā.
- 19. Paņēmiens saskaņā ar 18.punktu, kas a t š ķ i r a s ar to, ka morftna vai tā farmaceitiski pieņemama sāls koncentrācija ir zemāka par 50 % mas./mas.
- 20. Paņēmiens saskaņā ar 18.punktu, kas a t š ķ i r a s ar to, ka morftna vai tā farmaceitiski pieņemama sāls koncentrācija ir zemāka par 10 % mas./mas.
- 21. Paņēmiens saskaņā ar 18.punktu, kas a t š ķ i r a s ar to, ka morfīns vai tā farmaceitiski pieņemams sāls disperģēts suspensijā, šķīdumos, pulveros, gelos, ziedēs un krēmos.
- 22. Paņēmiens saskaņā ar 17.punktu, kas a t š ķ i r a s ar to, ka nazāla ievadīšanas (padeves) sistēmā ietilpst buferšķīdums morfīna vai tā farmaceitiski pieņemama sāls pH uzturēšanai, biezinātājs, mitrinātājs, absorbcijas palielinātājs un šo komponentu kombinācijas.
- 23. Paņēmiens saskaņā ar 22.punktu, kurā papildus ietilpst viena vai vairākas farmaceitiskas palīgvielas.
- 24. Paņēmiens saskaņā ar 22.punktu, kurā papildus ietilpst dispersijas (suspensijas) stabilizators.
- 25. Paņēmiens saskaņā ar 22.punktu, kas a t š ķ i r a s ar to, ka buferšķīdumu izvēlas no grupas, kas sastāv no acetāta, citrāta, prolamīna, karbonāta, fosfāta un šo buferšķīdumu kombinācijām.
- 26. Paņēmiens saskaņā ar 22.punktu, kas a t š ķ i r a s ar to, ka biezinātāju izvēlas no grupas, kas sastāv no metilcelulozes, ksantāna sveķiem, karboksimetilcelulozes, hidroksipropilcelulozes, karbomēra, polivinilspirta, alginātiem, gumiarābika, hitozāna un šo biezinātāju kombinācijām.
- 27. Paņēmiens saskaņā ar 22.punktu, kas a t š ķ i r a s ar to, ka mitrinātāju izvēlas no grupas, kas sastāv no sorbīta, glicerīna, minerāleļļas, augu eļļas un šo mitrinātāju kombinācijām. 4
- 28. Paņēmiens saskaņā ar 22.punktu, kas a t š ķ i r a s ar to, ka absorbcijas palielinātāju izvēlas no grupas, kas sastāv no nātrija laurilsulfata, nātrija salicilāta, oleīnskābes, lecitīna, dehidratēta spirta, Tween, Span, polioksila 40 stearāta, polioksietilēna 50 stearāta, dinātrija edetāta, propilēnglikola, glicerolmonooleāta, fuziātiem, žulta sāļiem, oktoksinola un šo absorbcijas palielinātāju kombinācijām.
- 29. Paņēmiens saskaņā ar 22.punktu, kas a t š ķ i r a s ar to, ka absorbcijas palielinātāju izvēlas no grupas, kas sastāv no anjonu, katjonu un nekatjonu absorbcijas palielinātājiem un to kombinācijām.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33453799A | 1999-06-16 | 1999-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV12859B true LV12859B (lv) | 2002-12-20 |
Family
ID=23307687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-01-169A LV12859B (lv) | 1999-06-16 | 2002-01-18 | Farmaceitiskas kompozīcijas ar morfīnu intranazālai ievadīšanai un to iegūšanas paņēmieni |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6677346B1 (lv) |
| EP (2) | EP1183027A4 (lv) |
| JP (1) | JP2003501467A (lv) |
| KR (1) | KR20020016831A (lv) |
| AU (1) | AU774175B2 (lv) |
| BG (1) | BG106221A (lv) |
| BR (1) | BR0012082A (lv) |
| CA (1) | CA2374877C (lv) |
| CZ (1) | CZ20014399A3 (lv) |
| DE (1) | DE10084709T1 (lv) |
| DK (1) | DK200101859A (lv) |
| EE (1) | EE200100677A (lv) |
| ES (1) | ES2197792B1 (lv) |
| FI (1) | FI20012462A (lv) |
| GB (1) | GB2367005A (lv) |
| HR (1) | HRP20010926A2 (lv) |
| HU (1) | HUP0201856A3 (lv) |
| IS (1) | IS6202A (lv) |
| LT (1) | LT4976B (lv) |
| LU (1) | LU90859B1 (lv) |
| LV (1) | LV12859B (lv) |
| MX (1) | MXPA01012879A (lv) |
| NO (1) | NO20015931L (lv) |
| NZ (1) | NZ515783A (lv) |
| PL (1) | PL352556A1 (lv) |
| SE (1) | SE0104203L (lv) |
| SI (1) | SI20850A (lv) |
| SK (1) | SK18172001A3 (lv) |
| TR (1) | TR200103613T2 (lv) |
| WO (1) | WO2000076506A1 (lv) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924797D0 (en) | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| WO2002024116A1 (en) * | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| US20030003113A1 (en) * | 2001-06-29 | 2003-01-02 | Lewandowski Leon J. | Individualized addiction cessation therapy |
| GB0210264D0 (en) * | 2002-05-03 | 2002-06-12 | Arakis Ltd | The treatment of pain and migraine headache |
| US20040102476A1 (en) * | 2002-11-25 | 2004-05-27 | Chan Tai Wah | High concentration formulations of opioids and opioid derivatives |
| US20050175679A1 (en) * | 2004-02-10 | 2005-08-11 | Michael Moshman | Controlled release formulations |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| NZ555501A (en) | 2004-11-24 | 2010-01-29 | Medpointe Healthcare Inc | Compositions comprising azelastine and methods of use thereof |
| US9415034B2 (en) * | 2005-01-05 | 2016-08-16 | National Defense Medical Center | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
| ES2277743B2 (es) * | 2005-06-02 | 2008-12-16 | Universidade De Santiago De Compostela | Nanoparticulas que comprenden quitosano y ciclodextrina. |
| JP5276982B2 (ja) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
| US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| BRPI0720434A2 (pt) * | 2006-12-22 | 2014-01-07 | Sigma Tau Ind Farmaceuti | Gel útil para liberação de fármacos oftálmicos |
| GB2477545B (en) * | 2010-02-05 | 2011-12-21 | Special Products Ltd | A liquid morphine composition for buccal administration |
| MX354249B (es) | 2011-05-13 | 2018-02-20 | Euro Celtique Sa | Formas de dosificación farmacéuticas intranasales que comprenden naloxona. |
| EP2877178A1 (en) | 2012-07-26 | 2015-06-03 | Wockhardt Limited | Pharmaceutical composition comprising diamorphine for intranasal administration |
| EP3082817A4 (en) * | 2013-12-18 | 2017-06-21 | Aegis Therapeutics, LLC | Compositions for drug administration |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| EP3242676B1 (en) | 2015-01-07 | 2023-10-04 | Tonix Pharmaceuticals Holding Corp. | Magnesium-containing oxytocin formulations and methods of use |
| CA3041308A1 (en) * | 2016-10-21 | 2018-04-26 | Somniferum Labs LLC | Method, system and apparatus for controlled delivery of opioid and other medications |
| WO2019076997A1 (en) * | 2017-10-20 | 2019-04-25 | Chiesi Farmaceutici S.P.A. | PHARMACEUTICAL FORMULATIONS COMPRISING AN OPIOID RECEPTOR AGONIST AS ACTIVE SUBSTANCES, METHODS OF MAKING THEM AND THERAPEUTIC USES THEREOF |
| EA202091615A1 (ru) | 2018-12-21 | 2021-03-05 | Аегис Терапьютикс, Ллс | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
| CN115804754A (zh) * | 2022-12-16 | 2023-03-17 | 广州新济药业科技有限公司 | 吗啡鼻喷剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4464376A (en) | 1982-07-22 | 1984-08-07 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
| GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| EP0689438B1 (en) * | 1993-03-26 | 2003-06-04 | Franciscus Wilhelmus Henricus Maria Merkus | Pharmaceutical compositions for intranasal administration of apomorphine |
| GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
| JP2001501212A (ja) * | 1996-09-27 | 2001-01-30 | ナステック ファーマシューティカル カンパニー インク | 睡眠促進用鼻腔内調製物及び同物を用いる方法 |
-
2000
- 2000-05-23 EP EP00936212A patent/EP1183027A4/en not_active Withdrawn
- 2000-05-23 EP EP04001252A patent/EP1419774A1/en not_active Withdrawn
- 2000-05-23 WO PCT/US2000/014157 patent/WO2000076506A1/en not_active Application Discontinuation
- 2000-05-23 JP JP2001502839A patent/JP2003501467A/ja active Pending
- 2000-05-23 ES ES200150086A patent/ES2197792B1/es not_active Expired - Lifetime
- 2000-05-23 SK SK1817-2001A patent/SK18172001A3/sk unknown
- 2000-05-23 AU AU51561/00A patent/AU774175B2/en not_active Ceased
- 2000-05-23 GB GB0128383A patent/GB2367005A/en not_active Withdrawn
- 2000-05-23 HU HU0201856A patent/HUP0201856A3/hu unknown
- 2000-05-23 NZ NZ515783A patent/NZ515783A/en unknown
- 2000-05-23 EE EEP200100677A patent/EE200100677A/xx unknown
- 2000-05-23 SI SI200020030A patent/SI20850A/sl not_active IP Right Cessation
- 2000-05-23 DE DE10084709T patent/DE10084709T1/de not_active Ceased
- 2000-05-23 KR KR1020017016009A patent/KR20020016831A/ko not_active Application Discontinuation
- 2000-05-23 CA CA002374877A patent/CA2374877C/en not_active Expired - Fee Related
- 2000-05-23 CZ CZ20014399A patent/CZ20014399A3/cs unknown
- 2000-05-23 BR BR0012082-0A patent/BR0012082A/pt not_active IP Right Cessation
- 2000-05-23 MX MXPA01012879A patent/MXPA01012879A/es unknown
- 2000-05-23 TR TR2001/03613T patent/TR200103613T2/xx unknown
- 2000-05-23 PL PL00352556A patent/PL352556A1/xx not_active Application Discontinuation
- 2000-06-15 US US09/594,916 patent/US6677346B1/en not_active Expired - Fee Related
-
2001
- 2001-12-04 NO NO20015931A patent/NO20015931L/no not_active Application Discontinuation
- 2001-12-12 DK DK200101859A patent/DK200101859A/da not_active Application Discontinuation
- 2001-12-13 LT LT2001119A patent/LT4976B/lt not_active IP Right Cessation
- 2001-12-13 HR HR20010926A patent/HRP20010926A2/hr not_active Application Discontinuation
- 2001-12-13 FI FI20012462A patent/FI20012462A/fi not_active IP Right Cessation
- 2001-12-13 LU LU90859A patent/LU90859B1/en active
- 2001-12-14 BG BG106221A patent/BG106221A/xx unknown
- 2001-12-14 IS IS6202A patent/IS6202A/is unknown
- 2001-12-14 SE SE0104203A patent/SE0104203L/ not_active Application Discontinuation
-
2002
- 2002-01-18 LV LVP-01-169A patent/LV12859B/lv unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2374877C (en) | Pharmaceutical formulations and methods comprising intranasal morphine | |
| AU775112B2 (en) | Compositions and methods comprising morphine gluconate | |
| JP2003501468A (ja) | アポモルヒネの経鼻送達 | |
| NZ213067A (en) | Composition for transdermal delivery of opioids | |
| JP2016529328A (ja) | 舌下ブプレノルフィンスプレー | |
| CN102905689A (zh) | 包含低剂量纳曲酮的液体鼻喷雾 | |
| US20090246273A1 (en) | Ketorolac Sublingual Spray for the Treatment of Pain | |
| EP2288334A1 (en) | Composition and method for transmucosal delivery of lofexidine | |
| US9283220B2 (en) | Compositions of opioid antagonists and methods for treating conditions caused by the varicella-zoster virus therewith | |
| US10874658B2 (en) | Sublingual opioid formulations containing naloxone | |
| JP2003512415A (ja) | ガランタミン及び甘味剤を含む経口液剤 | |
| WO2000076507A1 (en) | Method for increasing the solubility of morphine and pharmaceutical compositions prepared therefrom | |
| US20070248667A1 (en) | Tannate Compositions and Methods of Use | |
| WO1999012544A1 (en) | Intranasal formulation containing scopolamine and method of treating motion sickness | |
| CA3115195A1 (en) | Oromucosal solutions of zolpidem or pharmaceutically acceptable salts thereof |